LGND FY 2018 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$251M+78.2% YoY

Gross Profit

$245M97.5% margin

Operating Income

$164M65.1% margin

Net Income

$143M57.0% margin

EPS (Diluted)

$5.96

Cash Flow

Operating Cash Flow

$194M

Free Cash Flow

$182M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$700M

Stockholders' Equity

$561M

Cash & Equivalents

$718M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$251M	$141M	+78.2%
Gross Profit	$245M	$136M	+80.6%
Operating Income	$164M	$68M	+140.5%
Net Income	$143M	$13M	+1041.5%